August 22, 2014—Most drugmakers reportedly are not extending 340B pricing on orphan drugs to rural and freestanding cancer hospitals despite the Health Resources and Services Administration’s position that they are required by law to do so.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register.
Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)